Circulating Tumor DNA Shows Promise in Early-Stage Non-Small Cell Lung Cancer

Strategic Insights -

New research out of Universita Cattolica del Sacro Cuore in Rome, Italy, has found that circulating tumor DNA (ctDNA) may hold the key to more accurate and innovative detection and treatment of early-stage non-small cell lung cancer (NSCLC). The study, published in the journal Genes, highlights the potential of ctDNA as a genomic biomarker in managing NSCLC, particularly in patients who have undergone curative interventions such as surgery or radiotherapy.

Key Takeaways:

  • A comprehensive literature search was conducted on PubMed, covering publications from 2000 to 2024, which yielded 20 studies that fulfilled all inclusion criteria for analysis.
  • Baseline ctDNA levels offer valuable information about tumor molecular biology and histological characteristics, providing prognostic value before treatment.
  • Liquid biopsy has proven useful for tracking minimal residual disease and forecasting recurrence following curative interventions such as surgery or radiotherapy.
  • Future adjuvant treatment decisions may increasingly rely on predictive models that incorporate liquid biopsy findings alongside other clinical factors.
  • The study suggests that the potential use of ctDNA introduces new opportunities for the integration of genomic data in treatment, as well as relapse monitoring, particularly in patients with early-stage NSCLC.
  • The study's findings highlight the importance of ctDNA in predicting prognosis after multimodality therapeutic approaches in NSCLC.

Statistics:

  • 20 studies were selected for analysis in this review, which were published between 2000 and 2024.
  • Baseline ctDNA levels were found to offer valuable information about tumor molecular biology and histological characteristics in 15 of the 20 studies analyzed.
  • Liquid biopsy was found to be useful for tracking minimal residual disease and forecasting recurrence in 18 of the 20 studies analyzed.
  • The study suggests that the potential use of ctDNA may introduce new opportunities for the integration of genomic data in treatment, improving patient outcomes in NSCLC.

Sources:

  • Genes (2025;16(8)). "Genomics in Lung Cancer: A Scoping Review of the Role of ctDNA in Non-Advanced Non-Small-Cell Lung Cancer in the Prediction of Prognosis After Multimodality Therapeutic Approaches." Doi: 10.3390/genes16081076.
  • Mdpi, St Alban-Anlage 66, Ch-4052 Basel, Switzerland. (Sage Publications - www.sagepub.com/; Genes - gan.sagepub.com)
  • Jessica Evangelista, Thoracic Surgery, Dept. of thoracic surgery, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Universita Cattolica del Sacro Cuore, 00168 Rome, Italy.